



Predicting Long-Term Drug Release Kinetics from One Week of Elution Data in Poly(Ethylene-co-Vinyl Acetate) Drug-Eluting Implants: A Method to Accelerate Product Development

Jeff Haley, PhD





Sr. Manager Medical/Pharma, Celanese Engineered Materials

CRS 2022 Montreal, QC

July 13, 2022

Today's Agenda

- Poly(Ethylene Vinyl Acetate) Drug-Eluting Implants
- Using the Higuchi Model to Extrapolate In Vitro Drug Release
- Examples of Higuchi Model Extrapolation



The Use of VitalDose® EVA Platform in Drug Delivery

Long History of Use in US & EMEA Approved Products

EVA has over 20 years of use in approved parenteral drug products in the US and EMEA



Ophthalmic Insert &
Ocular Implant



Intravaginal Ring



Intrauterine Device




Subcutaneous
Implant (rod)

Ease of design & formulation

Biostable and Inert

Months to years release

Hot Melt Extruded Drug Delivery Systems with EVA




- VitalDose® EVA is blended with powdered API
- **Low melt temperature options** offer optimal stability and compatibility

- Powdered API and EVA are **combined and compounded into extrudate**
- Small quantities of API can be used to generate small volume samples


- The extrudate is pelletized for use in **extrusion or injection molding**
- Processing flexibility results in a **versatile range of form factors**

Drug Release from EVA is Controlled by Diffusion




Problem Statement: Can We Apply Simple Mathematical Models to Extrapolate Long-Term Release Data?

- In vitro release experiments for long-acting implants require lengthy periods of data collection.
- During early stages of proof-of-concept work, several rounds of iteration may be needed.
- Mathematical modeling streamlines development by extrapolating long-term release.




Interpreting Drug Release from Monolithic Systems Using the Higuchi Model


Time = 0



Time = t_1




Time = t_2



$$M(t) = A\sqrt{DC_s(2C_o - C_s)t}$$


The Higuchi Model Can be Used to Describe Drug Release from EVA



Hydrocortisone

MW = 362.46 g/mol

$$M(t) \sim \sqrt{t}$$




Data: Fu, Moyer, Hagemeyer. *Journal of Biomedical Materials Research* 12 (1978).

The Higuchi Model and the Percolation Threshold

Release kinetics have same functional dependance on time below and above the percolation threshold

Below the percolation threshold

Higuchi, T. J. *Pharm. Sci.* **50**, 874 (1961).



$$M(t) = A \sqrt{\underbrace{DC_s(2C_o - C_s)}_{\text{Time independent parameters that can be grouped into a constant}}} t$$

Time independent parameters that can be grouped into a constant

Above the percolation threshold

Higuchi, T. J. *Pharm. Sci.* **52**, 1145 (1963).




$$M(t) = A \sqrt{\underbrace{\frac{D_w \epsilon}{\tau} C_{sw}(2C_o - \epsilon C_{sw})}_{\text{Time independent parameters that can be grouped into a constant}}} t$$

Time independent parameters that can be grouped into a constant

$$M(t) = A K \sqrt{t}$$

Testing Predictions Below The Percolation Threshold



**Below the
percolation
threshold**

Hydrocortisone

Niacin

Cyclosporin




**Above the
percolation
threshold**

Islatrivir

BSA

Extrapolating In Vitro Release with the Higuchi Model




Hydrocortisone

MW = 362.46 g/mol

20 mg loading: $C_o = 0.075 \text{ g/cm}^3$

40 mg loading: $C_o = 0.15 \text{ g/cm}^3$




Data: Fu, Moyer, Hagemeyer. *Journal of Biomedical Materials Research* 12 (1978).


How Well Can We Predict the Full Release Curve Using Seven Days of Data?

A linear least squares fit can be used for the first seven days of data


$$M(t) = A K \sqrt{t}$$



Seven-Day Extrapolations Align with Experimental Data




$$M(t) = A K \sqrt{t}$$




$$\frac{dM}{dt} = \frac{1}{2} A \frac{K}{\sqrt{t}}$$

Limited Differences Exist in Prediction Quality Using 14 Days of Data




$$M(t) = A K \sqrt{t}$$





$$\frac{dM}{dt} = \frac{1}{2} A \frac{K}{\sqrt{t}}$$

Additional Molecules Below the Percolation Threshold can be Extrapolated




Niacin

MW = 123.1 g/mol




Cyclosporin

MW = 1203 g/mol



Testing Predictions Above The Percolation Threshold



**Below the
percolation
threshold**

Hydrocortisone

Niacin

Cyclosporin




**Above the
percolation
threshold**

Islatrivir

BSA

We Can Use Same Predictive Approach Above the Percolation Threshold


Extrapolating from Seven Days of Data



Islatravir

MW = 293.3 g/mol

EVA (9% VA) loaded with
API at levels of 40%, 50%,
and 60%.





Data: Barrett et al. Antimicrob
Agents Chemother. 62 (2018).

Long-Term BSA Release Can be Predicted from EVA

Extrapolating from Seven Days of Data

Samples exhibit small initial burst release that reduces the quality of the fit

**Bovine serum
albumin**
MW \approx 66K g/mol





Data: Rhine, Hsich, Langer. *J. Pharm. Sci.* **69**, 265 (1980).

Long-Term BSA Release Can be Predicted from EVA

Treating the y-Intercept as a Fitting Parameter Improves the Extrapolation

**Bovine serum
albumin**

MW \approx 66K g/mol






Summary

- It is possible to predict long-term release kinetics from a monolithic EVA implant using data derived from a short one to two-week study using the Higuchi equation
- In cases where samples exhibit a rapid initial burst release at the first timepoint, it still may be possible to make good predictions with the addition of an extra fitting parameter

Contact Information:
Jeff Haley
jeff.haley@celanese.com



Legal Disclaimer

Disclaimer & Notice to Users

This publication was printed based on Celanese's present state of knowledge, and Celanese undertakes no obligation to update it. Because conditions of product use are outside Celanese's control, Celanese makes no warranties, express or implied, and assumes no liability in connection with any use of this information. Nothing herein is intended as a license to operate under or a recommendation to infringe any patents.

Values shown are based on testing of laboratory test specimens and represent data that fall within the standard range of properties for natural material. These values alone do not represent a sufficient basis for any part design and are not intended for use in establishing maximum, minimum, or ranges of values for specification purposes. Colorants or other additives may cause significant variations in data values. Properties of molded parts can be influenced by a wide variety of factors including, but not limited to, material selection, additives, part design, processing conditions and environmental exposure. Any determination of the suitability of a particular material and part design for any use contemplated by the users and the manner of such use is the sole responsibility of the users, who must assure themselves that the material as subsequently processed meets the needs of their particular product or use.

To the best of our knowledge, the information contained in this publication is accurate; however, we do not assume any liability whatsoever for the accuracy and completeness of such information. The information contained in this publication should not be construed as a promise or guarantee of specific properties of our products. It is the sole responsibility of the users to investigate whether any existing patents are infringed by the use of the materials mentioned in this publication. Moreover, there is a need to reduce human exposure to many materials to the lowest practical limits in view of possible adverse effects. To the extent that any hazards may have been mentioned in this publication, we neither suggest nor guarantee that such hazards are the only ones that exist. We recommend that persons intending to rely on any recommendation or to use any equipment, processing technique or material mentioned in this publication should satisfy themselves that they can meet all applicable safety and health standards. We strongly recommend that users seek and adhere to the manufacturer's current instructions for handling each material they use, and entrust the handling of such material to adequately trained personnel only.

The products mentioned herein are not intended for use in medical or dental implants.

Celanese®, registered C-ball design and all other trademarks identified herein with ®, TM, SM, unless otherwise noted, are trademarks of Celanese or its affiliates.

© 2022 Celanese or its affiliates. All rights reserved.

Contact Information

Americas

8040 Dixie Highway, Florence, KY 41042 USA

Product Information Service

t: +1-800-833-4882 t: +1-859-372-3244

Customer Service

t: +1-800-526-4960 t: +1-859-372-3214

e: info-engineeredmaterials-am@celanese.com

Europe

Am Unisys-Park 1, 65843 Sulzbach, Germany

Product Information Service

t: +(00)-800-86427-531 t: +49-(0)-69-45009-1011

e: info-engineeredmaterials-eu@celanese.com

Asia

4560 Jinke Road, Zhang Jiang Hi Tech Park

Shanghai 201203 PRC

Customer Service

t: +86 21 3861 9266 f: +86 21 3861 9599

e: info-engineeredmaterials-asia@celanese.com



The chemistry inside innovation™